Investors / We Venture Capital
We Venture Capital
Corporate VC
We Venture Capital is the corporate venture arm of Werfen, a specialist diagnostics company. It invests in diagnostics start-ups and takes an active role in its portfolio companies, often through board engagement.
Invests inHealthcare & Biotech
In its own wordsdiagnosticsdigital healthlife sciencesbiotechhealthcare
Your fit with We Venture Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsWe Venture Capital lists 7 checked portfolio companies on its own site and is named in 2 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United Kingdom. It invests most often alongside Kurma Partners, 15th Rock and 8VC.
Counts come from funding rounds that name We Venture Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 1 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 12th | 7 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 85th | 14% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 20th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Kurma Partners | 2 |
| 15th Rock | 1 |
| 8VC | 1 |
| AIN Ventures | 1 |
| Amino Collective | 1 |
| Asabys Partners | 1 |
| British Business Bank | 1 |
| Civilization Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers7100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare We Venture Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with We Venture Capital| Date | Company | Stage |
|---|---|---|
| 30 Jun 2025 | Series A |
Round details for We Venture Capital
Amounts, full round histories and every co-investor in We Venture Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
7 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Axithra develops technology for rapid therapeutic drug monitoring at the point of need | Healthcare & Biotech | Portfolio page | ||
| Capitainer develops and provides microsampling devices for collecting precise volumes of blood, plasma, or fluids for diagnostics and monitoring | Healthcare & Biotech | Portfolio page | ||
| Deepull is developing technology to detect sepsis-causing pathogens and antibiotic resistance markers directly from blood | Healthcare & Biotech | Portfolio page | ||
| Oxford Cancer Analytics develops a platform for early cancer detection and generates evidence-based insights to support clinical decision-making in lung disease | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides nanopore technology for detecting and analyzing single molecules, including proteins and metabolites. | Healthcare & Biotech | Jun 2025Series A | Page + round | |
| Proton Intelligence is developing a wearable platform for continuous potassium monitoring for clinicians managing cardio-kidney disease. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page |
About this data
site last read 5 Nov 2026- Site
- weventurecapital.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 30 Jun 2025
- Companies checked
- 7
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get We Venture Capital's profile as data
Pull We Venture Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/weventurecapital.com
# also
GET /v1/firms/weventurecapital.com/portfolio
GET /v1/firms/weventurecapital.com/coinvestors
GET /v1/firms/weventurecapital.com/news